{
    "xml": "<topic id=\"PHP81558\" outputclass=\"clinicalMedicinalProductInformation\" type=\"clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information/singulair-chewable-tablets\" basename=\"singulair-chewable-tablets\" title=\"Singulair chewable tablets\">\n<title>Singulair<tm tmtype=\"reg\"/> chewable tablets</title>\n<topic id=\"PHP83191\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.9\" parent=\"/clinical-medicinal-product-information/singulair-chewable-tablets\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Includes aspartame equivalent to phenylalanine 674&#8239;micrograms/4&#8239;mg tablet and 842&#8239;micrograms/5&#8239;mg tablet.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP83190\" outputclass=\"nationalFunding\" rev=\"1.8\" parent=\"/clinical-medicinal-product-information/singulair-chewable-tablets\">\n<title>National funding/access decisions</title>\n<body>\n<section>\n<sectiondiv outputclass=\"smcDecisions\">\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\n<sectiondiv outputclass=\"smcDecision\">\n<sectiondiv>\n<p>The <i>Scottish Medicines Consortium</i> has advised (June 2007) that <i>Singulair</i>\n<tm tmtype=\"reg\"/> chewable tablets are restricted for use as an alternative to low-dose inhaled corticosteroids for children 2&#8211;14 years with mild persistent asthma who have not recently had serious asthma attacks that required oral corticosteroid use and who are not capable of using inhaled corticosteroids; <i>Singulair</i>\n<tm tmtype=\"reg\"/> chewable tablets should be initiated by a specialist in paediatric asthma.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" title=\"Clinical medicinal product information\" namespace=\"/clinical-medicinal-product-information\">Clinical medicinal product information</xref>\n</parents>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information\" title=\"Clinical medicinal product information\" count=\"1\" rel=\"link\">Clinical medicinal product information</xref>\n</links>\n</topic>",
    "id": "PHP81558",
    "outputclass": "clinicalMedicinalProductInformation",
    "type": "clinicalMedicinalProductInformation",
    "namespace": "/clinical-medicinal-product-information/singulair-chewable-tablets",
    "basename": "singulair-chewable-tablets",
    "title": "Singulair chewable tablets",
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Includes aspartame equivalent to phenylalanine 674 micrograms/4 mg tablet and 842 micrograms/5 mg tablet.",
                "html": "<p>Includes aspartame equivalent to phenylalanine 674&#8239;micrograms/4&#8239;mg tablet and 842&#8239;micrograms/5&#8239;mg tablet.</p>"
            }
        ]
    },
    "nationalFunding": {
        "smcDecisions": [
            {
                "type": "smcDecisions",
                "textContent": "The Scottish Medicines Consortium has advised (June 2007) that Singulair chewable tablets are restricted for use as an alternative to low-dose inhaled corticosteroids for children 2&#8211;14 years with mild persistent asthma who have not recently had serious asthma attacks that required oral corticosteroid use and who are not capable of using inhaled corticosteroids; Singulair chewable tablets should be initiated by a specialist in paediatric asthma.",
                "html": "<p>The <i>Scottish Medicines Consortium</i> has advised (June 2007) that <i>Singulair</i> <tm tmtype=\"reg\"/> chewable tablets are restricted for use as an alternative to low-dose inhaled corticosteroids for children 2&#8211;14 years with mild persistent asthma who have not recently had serious asthma attacks that required oral corticosteroid use and who are not capable of using inhaled corticosteroids; <i>Singulair</i> <tm tmtype=\"reg\"/> chewable tablets should be initiated by a specialist in paediatric asthma.</p>"
            }
        ]
    },
    "backlinks": {},
    "links": {
        "#clinicalMedicinalProductInformation": [
            {
                "id": "clinicalMedicinalProductInformation",
                "label": "Clinical medicinal product information",
                "type": "#clinicalMedicinalProductInformation"
            }
        ]
    }
}